1 / 34

Advanced Injectors Lecture BACD Regional Meeting London June 2008

Advanced Injectors Lecture BACD Regional Meeting London June 2008. MEDICAL DISCLOSURE:. Dr. Patrick J. Treacy is a Cosmetic Doctor presently on the Specialist Register in Ireland He holds a Dip Cos. Med Dip Dermatology, U.K. BTEC Laser Technology

mimi
Télécharger la présentation

Advanced Injectors Lecture BACD Regional Meeting London June 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Advanced Injectors Lecture BACD Regional Meeting London June 2008

  2. MEDICAL DISCLOSURE: • Dr. Patrick J. Treacy is a Cosmetic Doctor presently on the Specialist Register in Ireland • He holds a Dip Cos. Med Dip Dermatology, U.K. BTEC Laser Technology • Previously worked in the U. K. U.S. Australia, New Zealand, South Africa. • No financial interest or stock in Bioform nor do I receive any additional remuneration for giving this Advanced Training lecture.

  3. 1. Radiesse XL 2. Hand Volumisation

  4. PresentationContent • Product Information • Injection Techniques • What is Beauty? • The Aging Face • Upper and Mid Face • Lower Face • 7. HIV Lipodystrophy

  5. Key Characteristics • Safe • Bio-compatible • Bio-degradable • Effect 18-24 months • No migration • No pre-testing • No special handling

  6. CaHA Injectable ImplantKey Components • Structural component (~30%) • calcium and phosphate ions (Ca10(PO4)6(OH)2) • natural mineral (identical to human teeth & bone) • Gel carrier (~70%) • sodium carboxymethylcellulose • glycerine • sterile water Biocompatible and ‘GRAS’ Generally Recognized As Safe by FDA

  7. Uniform sphericalCaHA particles • Synthetic & pure • consistent, smooth & spherical • 25 to 45 microns • Size and shape facilitate • ease of injection • tissue infiltration • Natural mineral • non-antigenic, non-irritant, non-toxic • metabolizes via homeostatic mechanisms

  8. Calcium HydroxylapatiteMetabolisation CaHA performs as a filler initially.

  9. Calcium HydroxylapatiteMetabolisation Macrophages dissolve gel carrier.

  10. Calcium HydroxylapatiteMetabolisation Macrophages dissolve gel carrier & fibroblasts form new collagen.

  11. Calcium HydroxylapatiteMetabolisation New resident tissue (collagen) anchors microspherules of CaHA.

  12. Calcium HydroxylapatiteMetabolisation CaHA particles degrade and macrophages metabolize microspherules.

  13. Radiesse Safe Area Where is Radiesse Injected? Mid-Dermis Deep Dermis Dermis/SQ Jx. Sub-Q

  14. Injection technique 1 Inject retrograde in the mid-to-deep dermis near the junction of the subcutaneous tissue Miles Graivier, M.D. Roswell, GA.

  15. Injection technique 2 Inject large volumes antegrade in the deep dermis to level of the subcutaneous tissue Miles Graivier, M.D. Roswell, GA.

  16. Radiesse XL –a novel approach to pain free Radiesse

  17. Most injectors would agree that injectable treatments are better accomplished if the patient is kept comfortable. This makes the experience more pleasant for the patient which will keep them motivated to return for additional treatments. It also allows the injector to stay more focused on the injection process. I personally find significant patient discomfort to be a distraction.

  18. Traditional Anesthesia for Radiesse Most practitioners have typically utilized some form of local anesthesia: Topical Infraorbital, mental, supratrochlear, or supraorbital nerve blocks Local infiltration Depending upon the physician’s preference, usually 1% to 2% lidocaine with or without adrenaline is used.

  19. Disadvantage of Topical Agents The effect of topical agents is mainly limited to the epidermis to upper dermis. The deep dermis and subdermal tissues are not anesthetized. The patient still feels the passing of the needle and any discomfort related to the injection of the filler material.

  20. Disadvantages of nerve blocks May be quite uncomfortable. May cause additional bruising. Depending upon the treatment site, the nerve block may distort the area to be injected (e.g. the cheek and tear trough with an infraorbital nerve block). Require some knowledge of the location of key facial foramina to be successful. Therefore, the efficacy of the block may be dependent on the expertise of the injector.

  21. Disadvantages of Local Infiltration Directly injecting the treatment site distorts the area to be filled and can skew the injector’s judgment as to when optimal filling has been accomplished.

  22. Mixing Lidocaine with Radiesse Anesthetizes the treatment site as the injection process progresses. In most cases, the mixing of lidocaine with Radiesse obviates the need for nerve blocks or local infiltration. Most patients prefer injecting the mixed product to having nerve blocks. Some patients still will require or desire nerve blocks (sensitive patient, lip injections, etc.) The needle entry point (at least on the face) should still be anesthetized with a topical or local anaesthetic.

  23. Mixing Lidocaine with Radiesse Eliminates distortion of the treatment site from the local anesthetic. I find that most of my midface injections can be done just with a topical anesthetic on the oral mucosa. I now mix lidocaine with Radiesse for basically all of my injections. Eliminates the immediately post injection ”burning” that some patients used to complain of.

  24. Radiesse Mixing with Lidocaine Why mix Radiesse with lidocaine? Provide a less-painful alternative by eliminating the pain of a block and reducing discomfort for areas that are not easily blocked Prevent tissue distortion that may be caused by injecting local anesthetics Adjust the cohesiveness of Radiesse to use it as a layering rather than a bulking filler

  25. Mixing Lidocaine with Radiesse 0.15- 0.2 cc of 1 - 2% lidocaine with or without epinephrine is placed into an empty Radiesse 1.3cc syringe (A). Syringe A is connected to a 1.3 cc syringe (B) of Radiesse using a 3 Way tap (or Luer lock to Luer lock connector). The Radiesse contents are injected into syringe A and the mixture is then “swished” back and forth several times. 10 back and forth “swishes” are needed to obtain a homogeneous product. The mixture of Radiesse and lidocaine is then advanced back into the 1.3 cc syringe.

  26. Ailesbury Lidocaine Mixing Technique 0.15 -0.2cc of 2% plain Xylocaine +/- adrenaline is introduced using a previous 1.3ml Radiesse syringe and a 3 way lock with another 1.3ml syringe

  27. Similar US Lidocaine Mixing Technique 0.15 cc of 2% plain Xylocaine or 1% Lidocaine + Adr is introduced using a luer lock-to-luer lock connector (Baxa) and a 1 cc or 3 cc syringe

  28. Hand Volumisation As the hands age there is a loss of subcutaneous tissue in the dorsum of the hands. The hands become skeletonised with more prominent appearance of tendons and veins. This can be a “giveaway” to the patient’s true age despite efforts to rejuvenate the face. OLD YOUNG

  29. Signs of Ageing Hand Tendon Show Soft Tissue Atrophy Venous prominence Pigmentation Wrinkles

  30. Radiesse for Hand Volumisation Radiesse probably represents the best filler we currently have available for the dorsum of the hands. Simpler, less invasive, and more natural results than fat transfer. 5 – 10 minute procedure with no anesthesia needed other than mixing lidocaine (without adrenaline). Bolus injection into the subdermal areolar space. Massage Radiesse to distribute it evenly. Total Volume – 1.3 to 1.95 cc per hand

  31. PresentationContent

  32. Radiesse in Hands Immediately After 1.3 cc Before

  33. Radiesse for Hand Volumisation Before Immediately After 1.3 cc Mike Jasin, MD Tampa, FL

  34. PresentationContent

More Related